<DOC>
	<DOCNO>NCT00865878</DOCNO>
	<brief_summary>The purpose study determine compare safety efficacy broad area photodynamic therapy aminolevulinic acid ( ALA-PDT ) versus vehicle PDT ( VEH-PDT ) treatment actinic keratoses ( AK ) reduction new non-melanoma skin cancer ( NMSC ) scalp forearm solid organ transplant recipient subject receive chronic immunosuppressive therapy .</brief_summary>
	<brief_title>ALA-PDT Versus Vehicle PDT Treatment AK Reduction New NMSC Solid Organ Transplant Recipients</brief_title>
	<detailed_description>This Phase II multicenter , randomize , evaluator-blinded , vehicle-controlled , parallel group study photodynamic therapy organ transplant recipient subject treatment AK reduction new NMSC . Subjects randomize one follow two treatment group ( 1:1 ) receive topical Levulan® Kerastick® contain 20 % aminolevulinic acid HCL ( ALA , active study drug ) Kerastick® contain vehicle ingredient ( VEH ) . - Group 1 ALA apply entire scalp OR forearm 90 +/- 30 minute prior BLUE light treatment 16 minute 40 second - Group 2 VEH apply entire scalp OR forearm 90 +/- 30 minute prior BLUE light treatment 16 minute 40 second Treatment Area ( scalp forearm ) must least 2 NMSC past 12 month , must include continuous 25 cm2 Target Area contain minimum 3 AKs , eligible treatment Each subject may receive nine treatment . The initial four ( 4 ) ALA-PDT/VEH-PDT treatment give 4-5 week interval , remain five ( 5 ) treatment give every 6 +/-1 week . Post-treatment follow-up visit schedule occur 4 week subject 's final PDT .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>1 . Subject male nonpregnant female organ transplant ( kidney , liver , pancreas , lung , heart combination thereof ) recipient outpatient 18 year age old . Females must postmenopausal , surgically sterile use medically acceptable form birth control , negative urine pregnancy test Baseline visit . 2 . Subject provide write verbal informed consent . 3 . Subject least 3 actinic keratosis lesion continuous 25 cm2 Target Area within select anatomic treatment site ( scalp forearm ) . 4 . Subject history minimum 2 NMSC treatment area interest ( scalp OR forearm ) past 12 month 5 . Subject currently receive standard active pharmacologic immunosuppression 6 . Subject willing comply study instruction return clinic require visit . 7 . Subject Fitzpatrick skin type IIV . 1 . Subject pregnant , lactating , plan become pregnant study . 2 . Subject history cutaneous photosensitization , porphyria , hypersensitivity porphyrin photodermatosis . 3 . Subject skin pathology condition , investigator 's opinion , could interfere evaluation test product require use interfere topical systemic therapy . 4 . Subject condition , investigator 's opinion , would make unsafe subject participate research study . 5 . Subject currently enrol investigational drug ( include experimental immunosuppressive agent contain new chemical entity ) device study . Novel combination alternative dose regimen approve immunosuppressive agent allow . 6 . Subject receive investigational drug ( include experimental immunosuppressive agent contain new chemical entity ) treat investigational device within 30 day prior initiation treatment ( baseline ) . Novel combination alternative dose regimen approve immunosuppressive agent allow . 7 . Subject unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function . 8 . Subject may unreliable study include subject engage excessive alcohol intake drug abuse , subject unable return schedule followup visit . 9 . Subject know sensitivity one vehicle component ( ethyl alcohol , isopropyl alcohol , laureth 4 , polyethylene glycol ) . 10 . Subject active recurrent herpes simplex labialis infection treatment area outbreak within last 12 month place antiviral prophylaxis specify protocol . 11 . Subject use follow topical preparation select Treatment Area ( scalp OR forearm ) : Keratolytics include urea ( great 5 % ) , alpha hydroxyacids [ e.g . glycolic acid , lactic acid , etc . great 5 % ] , salicylic acid ( great 2 % ) within 2 day initiation treatment . 5FU , cryotherapy , diclofenac , imiquimod treatment AK within 2 week initiation treatment Retinoids , include tazarotene , adapalene , tretinoin , retinol , within 4 week initiation treatment . Microdermabrasion , laser ablative treatment , ALAPDT chemical peel within 8 week initiation treatment . Two ALA PDT treatment past 6 month 12 . Subject use systemic retinoid therapy within 6 month initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Actinic Keratoses</keyword>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Transplants</keyword>
</DOC>